X
All Data
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
While Cyxone continues to develop the oral administration form for T20K, the company has also decided to initiate a feasibility study on a subcutaneous administration form in Q2 2021. Finally, biomarker development to support both administration forms will be completed.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
